Inverness Medical Innovations, Inc., a leading provider of near-patient diagnostics, monitoring and health management solutions, announced that it intends to move the trading of its listed securities to the New York Stock Exchange (NYSE). The Company has filed its listing application with NYSE and currently expects its listings on NYSE to commence on January 6, 2009. Until that time the Company’s shares will continue to trade on Alternext (formerly the American Stock Exchange). The Company’s Common Stock will continue to trade under the symbol, “IMA” and its Series B Convertible Perpetual Preferred Stock will continue to trade under the symbol, “IMA.PR.B”.
Inverness Medical Innovations, Inc., a leading provider of near-patient diagnostics, monitoring and health management solutions, announced that it intends to move the trading of its listed securities to the New York Stock Exchange (NYSE). The Company has filed its listing application with NYSE and currently expects its listings on NYSE to commence on January 6, 2009. Until that time the Company’s shares will continue to trade on Alternext (formerly the American Stock Exchange). The Company’s Common Stock will continue to trade under the symbol, “IMA” and its Series B Convertible Perpetual Preferred Stock will continue to trade under the symbol, “IMA.PR.B”.
Ron Zwanziger, Inverness’ Chairman, Chief Executive Officer and President said, We are proud to be able to move our listings over to the New York Stock Exchange and offer our shareholders the increased liquidity and visibility available through this premier exchange. We look forward to a long and successful relationship with NYSE.
Duncan Niederauer, NYSE Euronext CEO, We are pleased to welcome Inverness, a leader in medical diagnostics products and health management, to our family of listed companies. Inverness recognizes the value and benefits of listing on the NYSE, and we look forward to serving the company and its shareholders